Literature DB >> 32373227

Erratum: βKlotho is identified as a target for theranostics in non-small cell lung cancer: Erratum.

Fan Li1, Xiyao Li1, Ziming Li2, Wenxiang Ji2, Shun Lu2, Weiliang Xia1.   

Abstract

[This corrects the article DOI: 10.7150/thno.35582.]. © The author(s).

Entities:  

Year:  2020        PMID: 32373227      PMCID: PMC7196295          DOI: 10.7150/thno.46029

Source DB:  PubMed          Journal:  Theranostics        ISSN: 1838-7640            Impact factor:   11.556


In our paper 1, Figure 3 should be corrected as follows.
Figure 3

High levels of KLB inhibit the proliferation and inhibits ERK, STAT3, AKT pathway of human NSCLC cells. A. Cancer cells were transfected with a pCDH-KLB expression vector (KLB-OE) or a control pCDH vector (KLB-EV). IF staining of Ki67(red) and DAPI (for nucleus, blue) in HCC15 and H520 cells after transfection. Scale bar = 50 μm. The right panel was % of Ki-67 positive cells. B. Colony formation in SK-MES-1 and H520 cells. C. (a) Cell viability assay of stably overexpressed (KLB-OE) and control (KLB-EV) cancer cells. (b) Protein levels of KLB and proliferation marker PCNA were determined by western blot. D. qRT-PCR analysis of stemness-related genes in (a) SK-MES-1 cells and (b) H520 cells. E. Overexpression of KLB suppressed ERK, STAT3, AKT pathway. Data were represented as mean and SEM from three independent experiments. * P < 0.05. ** P < 0.01. *** P < 0.001.

The corrected figures do not affect the original conclusions of the findings.
  1 in total

1.  βKlotho is identified as a target for theranostics in non-small cell lung cancer.

Authors:  Fan Li; Xiyao Li; Ziming Li; Wenxiang Ji; Shun Lu; Weiliang Xia
Journal:  Theranostics       Date:  2019-10-12       Impact factor: 11.556

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.